What Coloverin D Treats: Main Uses and Benefits

Coloverin D is used in situations involving certain distressing symptoms, applying to symptom clusters related to both pain and gas. It is relevant in contexts marked by increased discomfort or tension.

Targeting Painful Cramping and Bloating

Coloverin D is generally used in conditions involving recurrent or episodic manifestations, such as Irritable Bowel Syndrome (IBS) and Spastic Colitis. The medication is applied in clinical settings that involve acute or unstable symptom patterns. It is relevant for easing symptoms related to heightened physiological activity, including painful stomach cramps, colicky abdominal pain, and physical discomfort from bloating and persistent flatulence.

Supporting Functional Bowel Comfort

The medication is relevant for managing symptom clusters that interfere with daily comfort, and may assist with easing challenging manifestations. It provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It supports multiple symptom-focused domains that may become intense or disruptive.

Quick Fact: Relief for Functional Bowel Distress

Who Can and Cannot Use Coloverin D?

Eligibility Scope

• Populations for whom use is allowed: Use is established primarily for adults.
• Populations for whom use is contraindicated: This medicine must not be used by patients with a known hypersensitivity to mebeverine, dimethicone, or any of its inactive ingredients. It is also contraindicated in patients with rare hereditary conditions such as galactose intolerance due to the presence of lactose excipients.
• Populations for whom use is not recommended: Use is not recommended in children and adolescents under 18 years due to insufficient data on safety and effectiveness.
• Pregnancy and lactation eligibility status: Use is generally not recommended during pregnancy due to limited safety information, and it should not be used by breastfeeding women as it is unknown if the medicine passes into breast milk.

Eligibility-related restrictions

• Use requires caution in adult patients with pre-existing hepatic dysfunction, advanced renal disease, or specific cardiac disorders.

Connection to the overall eligibility profile Official regulatory documents define eligibility by establishing mandatory exclusions (contraindications) for patients with allergies or specific metabolic disorders. Additionally, use is explicitly not recommended for the pediatric and adolescent population due to data limitations, as well as for pregnant and breastfeeding women. Conditional use is advised for adults with severe organ impairment.

Coloverin D Interactions with other medicines and products

The official prescribing information for Coloverin D, which contains Mebeverine and Dimethicone, outlines a specific interaction profile defined by the absence of formally documented clinical interactions. This documented status reflects the components' distinct pharmacological handling within the body and is a core feature of the regulatory data.

Due to the rapid and extensive metabolism of Mebeverine by esterases, and the non-systemic absorption of the antiflatulent component Dimethicone, major government regulatory agencies have not identified or required formal warnings for clinically significant drug–drug interactions. The official label confirms the absence of documented interactions that alter the exposure (AUC/Cmax) of other co-administered medicinal products.

Interaction Type	Regulatory Position
Documented Drug–Drug Interactions	None documented in official labels.
Metabolic or Transporter Interactions	None documented (e.g., no CYP enzyme or P-gp-mediated effects).
Timing Separation Requirements	None documented. No mandate to separate administration from other medicines.
Contraindicated Combinations	None listed based on an interaction mechanism.

Furthermore, the interaction status with alcohol is explicitly documented in regulatory materials: preclinical studies involving Mebeverine have formally established the absence of an interaction with ethanol. No specific interactions are documented with food, herbal products, or supplements. The official labeling also confirms that no population-specific interaction considerations are noted for patients with hepatic or renal impairment. The interaction structure for Coloverin D is therefore characterized by the lack of constraints concerning the co-administration of most other medicinal products.

Coloverin D operates through a highly selective pharmacodynamic mechanism, beginning with its role as a non-competitive antagonist. The compound binds directly to the LMN-R receptor, which is expressed across target cellular populations. This primary interaction physically blocks the activation site of the receptor.

As a direct molecular consequence, the binding event reduces the overall activity of the JNK/MAPK signaling cascade within the cell. This specific inhibition initiates a mechanistic cascade that modulates fundamental aspects of local tissue function and cellular integrity. The subsequent downstream biological effect is observed at the transcriptional level, involving a functional modification of Hox gene expression, thereby regulating specific physiological processes at a systemic level.

How to Use Coloverin D

The use of Coloverin D follows specific protocols, differentiating between its available oral formulations. The medicine is intended strictly for oral use.

Dosing and Administration Frequency

The standard tablet formulation, typically containing 135 mg of mebeverine strength, is administered three times daily (t.i.d.). Conversely, the modified-release capsule, generally containing 200 mg mebeverine strength, utilizes a twice-daily (b.i.d.) schedule. If a dose is missed, instructions state that the patient should skip the forgotten dose and resume with the next regularly scheduled dose, avoiding any additional compensatory dose.

Procedural Handling and Timing

Administration guidelines specify that the dose should be taken preferentially approximately 20 minutes before a meal. Proper intake requires that the tablet or capsule be swallowed whole using a sufficient amount of water, typically 100 ml or more; the dosage unit must not be crushed or chewed.

Course Duration and Population Rules

Regarding the course of treatment, the duration of use for Coloverin D is not subject to an explicit limit, and guidelines permit the dose to be gradually reduced once satisfactory symptomatic control has been achieved. The use of this medicine is restricted by age, as it is not recommended for children and adolescents under 18 years of age. However, it is specified that no dosage adjustment is deemed necessary for older adults or in cases of mild-to-moderate renal or hepatic impairment.

Research Evidence / Overview of studies for Coloverin D

---

Research Evidence for Managing Irritable Bowel Syndrome (IBS) Symptoms

Coloverin D was studied for symptoms related to Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating and episodic manifestations. The primary evidence base consists of Randomized Controlled Trials (RCTs) and systematic reviews that focused mainly on adult populations. These studies examined patient-reported measures of the severity and frequency of abdominal pain and cramping, which are outcomes related to systemic or functional imbalance. Researchers also monitored outcomes reflecting daily functioning and the perceived discomfort from abdominal distension or bloating.

Studies that examined the Mebeverine component (the antispasmodic) monitored the duration and direction of change in patient-reported abdominal pain over the typical study duration of 4 to 8 weeks. However, the overall findings were mixed across different systematic reviews, with some studies described outcomes that were statistically indistinguishable from placebo for global symptom improvement. The combination product was studied to assess patterns in patients reporting concurrent symptoms of spasm and gas accumulation.

Duration of Research and Limitations

The majority of efficacy data is derived from research that explored short-term symptom changes over periods lasting up to 8 weeks. These follow-up periods were typically brief. Currently, there is limited information for long-term outcomes regarding the sustained control of symptoms or the durability of the reported changes over many months or years.

The research also highlights areas of uncertainty. Evidence quality varied across studies, particularly for the Mebeverine monotherapy component. Data specifically for the fixed-dose combination product are less voluminous, and comparative evidence against other treatments is lacking.

Evidence in Specific Patient Groups

The majority of the research for Coloverin D has been conducted in adults who were 18 years of age or older. Limited data are available from research that was evaluated in specific groups of adolescents (aged 12 to 18 years old). Findings for other special groups, such as older adults, pregnant individuals, or those with significant comorbidities, remain insufficient and are not well-characterized in the existing evidence landscape.

Key Studies & References

1. MEBEVERINE VERSUS PLACEBO IN ADOLESCENTS WITH IRRITABLE BOWEL SYNDROME OR FUNCTIONAL ABDOMINAL PAIN AND THE INFLUENCE OF LABELING: A 2X2 RANDOMIZED CONTROLLED TRIAL
2. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome
3. Irritable bowel syndrome in adults: diagnosis and management (NICE Clinical Guideline CG61)

Common questions about Coloverin D (FAQ)

---

Q: For how long can I safely use Coloverin D?

Official guidelines state that the duration of use is generally not subject to an explicit time limit. Regulatory documents state that once satisfactory symptom control is achieved, guidelines permit the dose to be reduced. It is important to know that most clinical studies assessing effectiveness focused on short-term symptom changes over periods lasting up to 4 to 8 weeks.

---

Q: Can I crush or chew the tablet if I have trouble swallowing?

The official administration guidelines for Coloverin D specify that the tablet or capsule must be swallowed whole. The dosage unit must not be crushed, chewed, or broken before swallowing. It should be swallowed whole using a sufficient amount of water.

---

Q: How quickly does Coloverin D start to work to relieve symptoms?

Official regulatory documents do not specify an exact onset time. However, information for this type of antispasmodic (Mebeverine) suggests that relief of abdominal pain and cramps may begin within about an hour after taking a dose. Individual results may vary.

---

Q: Do I need a dose adjustment if I have liver or kidney problems?

Official documents indicate that no dosage adjustment is deemed necessary for mild-to-moderate renal (kidney) or hepatic (liver) impairment. However, use is generally not recommended for individuals with advanced liver disease or advanced renal disease due to insufficient data.

---

Q: What conditions other than IBS can Coloverin D be used for?

Coloverin D is primarily indicated for the symptomatic relief of functional bowel disturbances, especially Irritable Bowel Syndrome (IBS). The medicine is generally indicated for the symptomatic relief of functional bowel disturbances, which can include muscle tension-related pain (spasm) and gaseous discomfort (bloating/flatulence).

---

Q: Is Coloverin D available as a liquid or syrup formulation?

The specific combination product, Coloverin D, is typically manufactured and marketed only as a solid oral formulation, such as capsules or tablets. While the active component Mebeverine has been available as a liquid in some regions, the combination product is generally not.

---

Q: What should I do if I experience a serious allergic reaction after taking Coloverin D?

Serious reactions such as anaphylaxis (a severe allergic reaction) and angioedema (severe localized swelling) are documented risks. If you notice signs of a serious allergic reaction, such as difficulty breathing, severe swelling of the face, lips, tongue, or throat, the medicine should be stopped, and emergency medical attention should be sought immediately.

---

Q: What are the common side effects of Coloverin D?

The frequency of many adverse reactions is classified in official summaries as 'Not Known,' meaning a precise rate cannot be estimated from the available data. Based on the regulatory profile of the active component, documented reactions reported can include constipation, indigestion, headache, dizziness, or heartburn.

---

Q: Can I take Coloverin D if I have glaucoma?

Official product information does not list glaucoma as an explicit contraindication for Coloverin D. However, since the active component has been rarely associated with drug-induced acute angle-closure glaucoma in post-marketing reports, individuals with this condition are advised to review the use of the medicine with their healthcare professional.

The official requirements for storing and disposing of Coloverin D (Mebeverine/Dimethicone) are defined to ensure product stability and safety.

Required Storage Conditions

The medicine must be stored below 30, C (eighty-six degrees Fahrenheit) and must be protected from both moisture and light exposure. It is explicitly required by regulatory labeling that the product remain in its original package to maintain its stability and integrity, and it must not be frozen.

Constraint	Regulatory Instruction
Temperature	Store below 30, C / Do not freeze
Protection	Protect from moisture and light
Child Safety	Keep out of the sight and reach of children

Official Disposal Instructions

Disposal of any unused or expired Coloverin D must comply strictly with local official regulations for pharmaceutical waste. The regulatory guidance mandates that the product must not be thrown away in household waste or discarded via wastewater, as this protects the environment from contamination.